Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA has expanded Dexcom's Stelo CGM clearance to children aged 2 and older who don't use insulin — making it the first OTC continuous glucose monitor approved for pediatric use. But pediatric endocrinologists are sounding the alarm, warning that unvalidated glucose thresholds, misinterpretation of normal fluctuations, and anxiety-driven overuse could lead to unnecessary testing and medicalization of healthy kids.
The FDA cleared Dexcom's Stelo Glucose Biosensor System for children aged 2 and older in June 2026, expanding its original 2024 approval for adults 18+. The device — available without a prescription — is now indicated for kids with diabetes managed on oral medications, as well as those who want to track how diet and exercise affect their glucose levels. Dexcom called it a milestone for families amid rising rates of youth-onset type 2 diabetes.
But not everyone is celebrating. Pediatric endocrinologists are raising red flags about the real-world implications of putting CGMs in the hands of families without clinical guidance. The core concern: glucose reference ranges for children haven't been validated for OTC use, meaning normal fluctuations could easily be misread as warning signs — triggering unnecessary doctor visits, testing, and even disordered eating.
Key Takeaways:
Why it matters: As CGM technology becomes more accessible, the line between useful health insight and anxiety-fueling data overload gets blurry — especially for kids. Without validated pediatric benchmarks, clinicians may face a wave of worried families seeking answers to questions the data can't yet reliably answer.
